Motif ID | Motif Logo | Scanned Score Distribution | Frequency of Motif | Replicability Score | Evolutionary Conservation Score | Gene Targets | Gene Ontology of CpGMM targets |
---|---|---|---|---|---|---|---|
CG_h1r2_promoter_n_PM_12_203_11 | ![]() |
![]() |
3 | 0.75 | 5.52E-05 | ENO1, CD74 | macrophage migration inhibitory factor binding [MF], macrophage migration inhibitory factor receptor complex [CC], glycolysis [BP], macrophage migration inhibitory factor signaling pathway [BP], NOS2-CD74 complex [CC] |
CG_h1r2_promoter_n_PM_12_298_14 | ![]() |
![]() |
2 | 0.5 | 1.30E-05 | SGSH, APOB | mature chylomicron [CC], chylomicron remnant [CC], intermediate-density lipoprotein particle [CC], N-sulfoglucosamine sulfohydrolase activity [MF] |
CG_h1r2_promoter_n_PM_12_145_6 | ![]() |
![]() |
1 | 0.25 | 2.24E-04 | IRF7 | regulation of MyD88-independent toll-like receptor signaling pathway [BP] |
CG_h1r2_promoter_n_PM_12_202_7 | ![]() |
![]() |
1 | 0.25 | 1.11E-04 | MTFMT, APOB, PLAGL2 | chylomicron assembly [BP], mature chylomicron [CC], chylomicron remnant [CC], methionyl-tRNA formyltransferase activity [MF], post-embryonic development [BP] |
CG_h1r2_promoter_n_PM_14_63_4 | ![]() |
![]() |
1 | 0.25 | 2.78E-05 | TGFB1, ENTPD5, DENND6A, SBF1 | defense response to fungus, incompatible interaction [BP], negative regulation of hyaluronan biosynthetic process [BP], positive regulation of NAD+ ADP-ribosyltransferase activity [BP], Rab guanyl-nucleotide exchange factor activity [MF], guanosine-diphosphatase activity [MF] |
CG_h1r2_promoter_n_PM_12_2_10 | ![]() |
![]() |
2 | 0.5 | 7.09E-05 | TFF2, CDH17, SLC2A1, SLC23A1 | dehydroascorbic acid transporter activity [MF], basolateral plasma membrane [CC], CXCR4 chemokine receptor binding [MF], L-ascorbic acid metabolic process [BP], dehydroascorbic acid transport [BP] |
CG_h1r2_promoter_n_PM_14_56_17 | ![]() |
![]() |
2 | 0.5 | 4.02E-05 | STAT1 | regulation of interferon-gamma-mediated signaling pathway [BP] |
CG_h1r2_promoter_n_PM_12_125_12 | ![]() |
![]() |
2 | 0.5 | 5.42E-05 | GOT2 | L-aspartate:2-oxoglutarate aminotransferase activity [MF], aspartate metabolic process [BP], glutamate catabolic process to aspartate [BP], L-phenylalanine:2-oxoglutarate aminotransferase activity [MF], glutamate catabolic process to 2-oxoglutarate [BP], aspartate catabolic process [BP], aspartate biosynthetic process [BP], 4-hydroxyproline catabolic process [BP], kynurenine-oxoglutarate transaminase activity [MF] |
CG_h1r2_promoter_n_PM_12_23_7 | ![]() |
![]() |
2 | 0.5 | 3.68E-04 | CSAD, TXN | sulfinoalanine decarboxylase activity [MF], response to thyroxine stimulus [BP] |
CG_h1r2_promoter_n_PM_12_214_5 | ![]() |
![]() |
2 | 0.5 | 1.10E-05 | TRMT112 | peptidyl-glutamine methylation [BP] |
CG_h1r2_promoter_n_PM_12_49_12 | ![]() |
![]() |
2 | 0.25 | 4.03E-04 | CCL23 | negative regulation of C-C chemokine binding [BP] |
CG_h1r2_promoter_n_PM_12_147_7 | ![]() |
![]() |
2 | 0.25 | 9.91E-05 | HEYL, SLC30A4 | proximal tubule development [BP], microsatellite binding [MF], regulation of sequestering of zinc ion [BP], negative regulation of androgen receptor activity [BP], AF-1 domain binding [MF] |
CG_h1r2_promoter_n_PM_12_228_5 | ![]() |
![]() |
2 | 0.5 | 1.94E-04 | CENPV, MFSD10 | centromeric heterochromatin assembly [BP], tetracycline transport [BP], tetracycline transporter activity [MF] |
CG_h1r2_promoter_n_PM_12_60_8 | ![]() |
![]() |
2 | 0.5 | 1.33E-04 | PDF, GNL1, ADPGK, IL12RB1 | interleukin-23 receptor complex [CC], interleukin-23-mediated signaling pathway [BP], interleukin-12 receptor complex [CC], peptide deformylase activity [MF], ADP-specific glucokinase activity [MF], T cell mediated immunity [BP], interleukin-12 receptor activity [MF] |
CG_h1r2_promoter_n_PM_14_32_6 | ![]() |
![]() |
1 | 0.25 | 2.46E-05 | PPAP2B | canonical Wnt receptor signaling pathway involved in positive regulation of endothelial cell migration [BP], canonical Wnt receptor signaling pathway involved in positive regulation of wound healing [BP], canonical Wnt receptor signaling pathway involved in positive regulation of cell-cell adhesion [BP] |
CG_h1r2_promoter_n_PM_12_288_4 | ![]() |
![]() |
1 | 0.25 | 6.05E-05 | WNT7B, PXN | establishment or maintenance of polarity of embryonic epithelium [BP], BH4 domain binding [MF], outer medullary collecting duct development [BP] |
CG_h1r2_promoter_n_PM_12_119_8 | ![]() |
![]() |
3 | 0.5 | 6.58E-05 | RPS6KA5, DIMT1 | histone H2A-S1 phosphorylation [BP], 18S rRNA (adenine(1779)-N(6)/adenine(1780)-N(6))-dimethyltransferase activity [MF] |
CG_h1r2_promoter_n_PM_12_126_7 | ![]() |
![]() |
2 | 0.5 | 3.26E-04 | CASP3, FOXP3 | nuclear fragmentation involved in apoptotic nuclear change [BP], positive regulation of peripheral T cell tolerance induction [BP], positive regulation of immature T cell proliferation in thymus [BP], positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation [BP], B cell homeostasis [BP], T cell homeostasis [BP], negative regulation of CREB transcription factor activity [BP], negative regulation of T cell proliferation [BP], negative regulation of activated T cell proliferation [BP], negative regulation of isotype switching to IgE isotypes [BP], negative regulation of histone deacetylation [BP] |
CG_h1r2_promoter_n_PM_12_117_9 | ![]() |
![]() |
1 | 0.25 | 6.55E-05 | SIX1, PGGT1B | CAAX-protein geranylgeranyltransferase complex [CC], myoblast migration [BP], positive regulation of ureteric bud formation [BP], ureter smooth muscle cell differentiation [BP], regulation of synaptic growth at neuromuscular junction [BP], regulation of branch elongation involved in ureteric bud branching [BP], negative regulation of branching involved in ureteric bud morphogenesis [BP], positive regulation of mesenchymal cell proliferation involved in ureter development [BP], negative regulation of nitric-oxide synthase biosynthetic process [BP], CAAX-protein geranylgeranyltransferase activity [MF], positive regulation of secondary heart field cardioblast proliferation [BP] |
CG_h1r2_promoter_n_PM_12_46_7 | ![]() |
![]() |
2 | 0.25 | 2.00E-05 | DOC2B | calcium ion-dependent exocytosis of neurotransmitter [BP] |
CG_h1r2_promoter_n_PM_12_101_8 | ![]() |
![]() |
2 | 0.25 | 4.81E-05 | SLC7A10, RYK, LRP5L | D-alanine transport [BP], Wnt-protein binding [MF], Wnt-activated receptor activity [MF] |
CG_h1r2_promoter_n_PM_12_59_8 | ![]() |
![]() |
2 | 0.5 | 4.64E-05 | COL2A1, VKORC1 | collagen type II [CC], vitamin-K-epoxide reductase (warfarin-sensitive) activity [MF] |
CG_h1r2_promoter_n_PM_12_169_10 | ![]() |
![]() |
2 | 0.5 | 2.87E-04 | COG4 | Golgi vesicle prefusion complex stabilization [BP] |
CG_h1r2_promoter_n_PM_12_130_5 | ![]() |
![]() |
1 | 0.25 | 1.61E-04 | KLF4, TFF2, OTUD7B | protein K11-linked deubiquitination [BP], negative regulation of chemokine (C-X-C motif) ligand 2 production [BP], positive regulation of hemoglobin biosynthetic process [BP], CXCR4 chemokine receptor binding [MF], negative regulation of muscle hyperplasia [BP], sequence-specific DNA binding transcription factor recruiting transcription factor activity [MF], negative regulation of inflammatory response [BP] |
CG_h1r2_promoter_n_PM_12_21_8 | ![]() |
![]() |
1 | 0.25 | 3.29E-04 | ACSL6 | positive regulation of plasma membrane long-chain fatty acid transport [BP] |
CG_h1r2_promoter_n_PM_12_139_9 | ![]() |
![]() |
1 | 0.25 | 4.10E-05 | CENPJ | gamma-tubulin small complex [CC] |
CG_h1r2_promoter_n_PM_12_28_4 | ![]() |
![]() |
2 | 0.5 | 6.45E-05 | ACACA, IL4I1 | acetyl-CoA carboxylase activity [MF], L-amino-acid oxidase activity [MF], malonyl-CoA biosynthetic process [BP] |
CG_h1r2_promoter_n_PM_12_282_8 | ![]() |
![]() |
1 | 0.25 | 1.07E-05 | ACER1, TTPA, RAB11FIP5, RAP2C, FOXJ1 | negative regulation of germinal center formation [BP], central tolerance induction [BP], response to pH [BP], dihydroceramidase activity [MF], negative regulation of humoral immune response mediated by circulating immunoglobulin [BP], recycling endosome membrane [CC], glomerular parietal epithelial cell development [BP], response to alkalinity [BP], negative regulation of establishment of blood-brain barrier [BP], positive regulation of lung ciliated cell differentiation [BP], positive regulation of central B cell tolerance induction [BP] |
CG_h1r2_promoter_n_PM_12_255_5 | ![]() |
![]() |
2 | 0.5 | 7.42E-05 | DNPH1 | nucleoside deoxyribosyltransferase activity [MF], deoxyribonucleoside 5'-monophosphate N-glycosidase activity [MF] |
CG_h1r2_promoter_n_PM_12_115_5 | ![]() |
![]() |
1 | 0.25 | 1.49E-04 | RPL22L1 | ribosome [CC] |
CG_h1r2_promoter_n_PM_12_71_8 | ![]() |
![]() |
1 | 0.25 | 2.79E-04 | VCPIP1 | endoplasmic reticulum membrane fusion [BP], Golgi reassembly [BP] |
CG_h1r2_promoter_n_PM_12_252_10 | ![]() |
![]() |
3 | 0.75 | 1.18E-05 | MYBPC3, LONP1 | C zone [CC], mitochondrial heavy strand promoter anti-sense binding [MF], oxidation-dependent protein catabolic process [BP], mitochondrial light strand promoter anti-sense binding [MF] |
CG_h1r2_promoter_n_PM_12_19_7 | ![]() |
![]() |
1 | 0.25 | 1.62E-04 | DMPK, NANOS2 | regulation of excitatory postsynaptic membrane potential involved in skeletal muscle contraction [BP], germ-line stem cell maintenance [BP], myosin phosphatase regulator activity [MF] |
CG_h1r2_promoter_n_PM_12_144_9 | ![]() |
![]() |
2 | 0.5 | 4.39E-05 | NEDD4 | negative regulation of vascular endothelial growth factor receptor signaling pathway [BP], beta-2 adrenergic receptor binding [MF], phosphothreonine binding [MF], negative regulation of transcription from RNA polymerase II promoter in response to UV-induced DNA damage [BP], glucocorticoid receptor signaling pathway [BP], negative regulation of sodium ion transport [BP], ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway [BP], transmission of virus [BP], progesterone receptor signaling pathway [BP], development involved in symbiotic interaction [BP] |
CG_h1r2_promoter_n_PM_12_24_5 | ![]() |
![]() |
2 | 0.5 | 1.24E-04 | MKNK1, RPL30, BRAF, MOB1A, RILPL2, SPG11 | cytosol [CC] |
CG_h1r2_promoter_n_PM_14_20_6 | ![]() |
![]() |
3 | 0.5 | 1.23E-04 | TMLHE, AGMAT, CPT1A | long-chain fatty acid metabolic process [BP], carnitine metabolic process [BP], trimethyllysine dioxygenase activity [MF], agmatinase activity [MF], putrescine biosynthetic process from arginine [BP] |
CG_h1r2_promoter_n_PM_12_176_16 | ![]() |
![]() |
3 | 0.75 | 4.42E-05 | LCT, WNT5A, RERE | poly-glutamine tract binding [MF], lactase activity [MF], receptor tyrosine kinase-like orphan receptor binding [MF] |
CG_h1r2_promoter_n_PM_12_236_16 | ![]() |
![]() |
1 | 0.25 | 2.79E-04 | PEX19 | peroxisome membrane class-1 targeting sequence binding [MF], negative regulation of lipid binding [BP] |
CG_h1r2_promoter_n_PM_12_204_8 | ![]() |
![]() |
2 | 0.5 | 3.62E-05 | CTSB, TLR9, CSF1R, KLF9, CD209 | innate immune response [BP], cellular response to thyroid hormone stimulus [BP], positive regulation of chemokine production [BP] |
CG_h1r2_promoter_n_PM_12_5_10 | ![]() |
![]() |
2 | 0.5 | 3.95E-05 | BRD1, SUPT7L, TTPA | negative regulation of establishment of blood-brain barrier [BP], histone H3 acetylation [BP] |
CG_h1r2_promoter_n_PM_12_287_9 | ![]() |
![]() |
2 | 0.5 | 8.12E-06 | WNT4 | positive regulation of aldosterone biosynthetic process [BP], thyroid-stimulating hormone-secreting cell differentiation [BP], positive regulation of cortisol biosynthetic process [BP], negative regulation of testosterone biosynthetic process [BP], negative regulation of testicular blood vessel morphogenesis [BP], female sex determination [BP], paramesonephric duct development [BP], renal vesicle induction [BP], negative regulation of male gonad development [BP], positive regulation of dermatome development [BP], tertiary branching involved in mammary gland duct morphogenesis [BP] |
CG_h1r2_promoter_n_PM_12_283_15 | ![]() |
![]() |
4 | 0.5 | 4.88E-05 | TRERF1, NR4A2, PIEZO2, SALL2, COQ3, CREBZF | sequence-specific DNA binding transcription factor activity [MF], 2-polyprenyl-6-methoxy-1,4-benzoquinone methyltransferase activity [MF], habenula development [BP], mechanically-gated ion channel activity [MF], 3-demethylubiquinone-9 3-O-methyltransferase activity [MF], hexaprenyldihydroxybenzoate methyltransferase activity [MF] |
CG_h1r2_promoter_n_PM_12_52_7 | ![]() |
![]() |
2 | 0.5 | 1.02E-04 | LCT, CYP11A1, ANGPT2 | cholesterol monooxygenase (side-chain-cleaving) activity [MF], maternal process involved in female pregnancy [BP], negative regulation of positive chemotaxis [BP], response to genistein [BP], lactase activity [MF] |
CG_h1r2_promoter_n_PM_12_94_7 | ![]() |
![]() |
2 | 0.5 | 7.68E-05 | UGDH, REV1 | deoxycytidyl transferase activity [MF], UDP-glucose 6-dehydrogenase activity [MF], error-prone translesion synthesis [BP] |
CG_h1r2_promoter_n_PM_12_183_9 | ![]() |
![]() |
2 | 0.5 | 3.42E-05 | ADPRHL1, ESCO1 | post-translational protein acetylation [BP], ADP-ribosylarginine hydrolase activity [MF], protein de-ADP-ribosylation [BP] |
CG_h1r2_promoter_n_PM_12_149_6 | ![]() |
![]() |
2 | 0.5 | 5.22E-05 | WARS | tryptophan-tRNA ligase activity [MF], tryptophanyl-tRNA aminoacylation [BP] |
CG_h1r2_promoter_n_PM_12_80_8 | ![]() |
![]() |
2 | 0.5 | 3.69E-05 | LGSN | glutamate-ammonia ligase activity [MF], glutamine biosynthetic process [BP] |
CG_h1r2_promoter_n_PM_14_24_7 | ![]() |
![]() |
3 | 0.75 | 2.02E-05 | ACSL6 | positive regulation of plasma membrane long-chain fatty acid transport [BP] |
CG_h1r2_promoter_n_PM_12_208_9 | ![]() |
![]() |
2 | 0.5 | 1.89E-05 | IDI2, MFNG, ATRX | helicase activity [MF], isopentenyl-diphosphate delta-isomerase activity [MF], O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity [MF], dimethylallyl diphosphate biosynthetic process [BP] |
CG_h1r2_promoter_n_PM_12_237_6 | ![]() |
![]() |
3 | 0.75 | 7.56E-05 | ANGPT2 | negative regulation of positive chemotaxis [BP] |
CG_h1r2_promoter_n_PM_12_88_16 | ![]() |
![]() |
1 | 0.25 | 1.23E-04 | FLT1 | vascular endothelial growth factor receptor-1 signaling pathway [BP], VEGF-B-activated receptor activity [MF], VEGF-A-activated receptor activity [MF], placental growth factor-activated receptor activity [MF] |
CG_h1r2_promoter_n_PM_12_6_7 | ![]() |
![]() |
1 | 0.25 | 6.84E-05 | SLC25A29, PGAM2, INTS1 | acyl carnitine transmembrane transporter activity [MF], 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase activity [MF], U2 snRNA 3'-end processing [BP] |
CG_h1r2_promoter_n_PM_14_39_7 | ![]() |
![]() |
1 | 0.25 | 5.96E-05 | SLC30A2 | positive regulation of sequestering of zinc ion [BP] |
CG_h1r2_promoter_n_PM_12_206_5 | ![]() |
![]() |
1 | 0.25 | 4.51E-05 | MC2R, ANKLE2, FASN, CYP2J2 | 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activity [MF], 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activity [MF], enoyl-[acyl-carrier-protein] reductase (NADPH, B-specific) activity [MF], [acyl-carrier-protein] S-acetyltransferase activity [MF], linoleic acid epoxygenase activity [MF], arachidonic acid 11,12-epoxygenase activity [MF], 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity [MF], arachidonic acid 14,15-epoxygenase activity [MF], mitotic nuclear envelope reassembly [BP], corticotropin receptor activity [MF] |
CG_h1r2_promoter_n_PM_12_264_11 | ![]() |
![]() |
2 | 0.5 | 2.04E-04 | TIPIN | regulation of DNA replication involved in S phase [BP] |
CG_h1r2_promoter_n_PM_14_22_7 | ![]() |
![]() |
2 | 0.5 | 2.98E-05 | HSPA5 | regulation of protein folding in endoplasmic reticulum [BP] |
CG_h1r2_promoter_n_PM_12_181_8 | ![]() |
![]() |
3 | 0.5 | 1.46E-05 | MTHFR, LPAR1, SOST | lysophosphatidic acid receptor activity [MF], negative regulation of Wnt receptor signaling pathway involved in dorsal/ventral axis specification [BP], methylenetetrahydrofolate reductase (NADPH) activity [MF], positive regulation of smooth muscle cell chemotaxis [BP] |
CG_h1r2_promoter_n_PM_12_62_7 | ![]() |
![]() |
1 | 0.25 | 2.03E-04 | GAMT | guanidinoacetate N-methyltransferase activity [MF] |
CG_h1r2_promoter_n_PM_14_6_9 | ![]() |
![]() |
6 | 1.0 | 3.15E-05 | CENPV, BAZ1A | centromeric heterochromatin assembly [BP], ACF complex [CC], chromatin remodeling [BP], CHRAC [CC] |
CG_h1r2_promoter_n_PM_12_136_4 | ![]() |
![]() |
2 | 0.5 | 8.20E-05 | MSTN | negative regulation of skeletal muscle tissue growth [BP] |
CG_h1r2_promoter_n_PM_12_102_4 | ![]() |
![]() |
1 | 0.25 | 1.26E-04 | OSR1 | metanephric smooth muscle tissue development [BP], metanephric cap mesenchymal cell proliferation involved in metanephros development [BP], specification of posterior mesonephric tubule identity [BP], intermediate mesoderm development [BP], renal vesicle progenitor cell differentiation [BP], specification of anterior mesonephric tubule identity [BP], posterior mesonephric tubule development [BP], metanephric interstitial cell development [BP] |
CG_h1r2_promoter_n_PM_12_73_12 | ![]() |
![]() |
1 | 0.25 | 1.66E-04 | MYO1A, WDR1, FGFR1, WNT5A | sensory perception of sound [BP], mesenchymal-epithelial cell signaling [BP], receptor tyrosine kinase-like orphan receptor binding [MF], positive regulation of mesenchymal cell proliferation [BP] |
CG_h1r2_promoter_n_PM_12_43_10 | ![]() |
![]() |
3 | 0.5 | 7.39E-05 | PIP5K1C, GRIK5, INSR, ADRB3, IGFBP7, CHRNE, NEU1, PDLIM7 | cell junction [CC], insulin-activated receptor activity [MF], beta3-adrenergic receptor activity [MF], receptor complex [CC], insulin-like growth factor binding [MF], synaptic vesicle exocytosis [BP] |
CG_h1r2_promoter_n_PM_12_44_6 | ![]() |
![]() |
2 | 0.5 | 1.05E-04 | MECP2 | double-stranded methylated DNA binding [MF] |
CG_h1r2_promoter_n_PM_14_54_8 | ![]() |
![]() |
1 | 0.25 | 2.72E-05 | UBE2V1 | UBC13-UEV1A complex [CC] |
CG_h1r2_promoter_n_PM_14_43_8 | ![]() |
![]() |
2 | 0.5 | 2.72E-05 | KARS | lysine-tRNA ligase activity [MF], microtubule cytoskeleton [CC] |
CG_h1r2_promoter_n_PM_12_58_8 | ![]() |
![]() |
1 | 0.25 | 7.75E-05 | TFF2 | CXCR4 chemokine receptor binding [MF] |
CG_h1r2_promoter_n_PM_12_146_8 | ![]() |
![]() |
1 | 0.25 | 1.66E-04 | ZC3H3, ADORA3 | regulation of mRNA export from nucleus [BP], positive regulation of mucus secretion [BP], histamine secretion by mast cell [BP] |
CG_h1r2_promoter_n_PM_14_45_10 | ![]() |
![]() |
3 | 0.75 | 4.67E-05 | CBS, BBC3, MAPK1, BUD13, GPX1 | cystathionine beta-synthase activity [MF], cysteine biosynthetic process via cystathionine [BP], induction of apoptosis [BP], RES complex [CC], homocysteine catabolic process [BP], cysteine biosynthetic process from serine [BP], mammary gland epithelial cell proliferation [BP] |
CG_h1r2_promoter_n_PM_12_75_8 | ![]() |
![]() |
1 | 0.25 | 1.92E-05 | FLT1, SULF2, NPHS1, TARBP1 | vascular endothelial growth factor receptor-1 signaling pathway [BP], placental growth factor-activated receptor activity [MF], glomerular basement membrane development [BP], VEGF-A-activated receptor activity [MF], VEGF-B-activated receptor activity [MF], RNA methyltransferase activity [MF] |
CG_h1r2_promoter_n_PM_12_271_10 | ![]() |
![]() |
1 | 0.25 | 1.42E-05 | ENO1, VIMP, TXN2 | regulation of nitric oxide metabolic process [BP], cell redox homeostasis [BP], response to glucose stimulus [BP], gluconeogenesis [BP], response to hormone stimulus [BP] |
CG_h1r2_promoter_n_PM_12_221_9 | ![]() |
![]() |
2 | 0.5 | 2.06E-04 | TYMP, TBXA2R | pyrimidine-nucleoside phosphorylase activity [MF], thymidine phosphorylase activity [MF], thromboxane A2 receptor activity [MF] |
CG_h1r2_promoter_n_PM_14_25_12 | ![]() |
![]() |
2 | 0.5 | 1.04E-04 | SDHB, KLK14, BST2, MTFMT | negative regulation of plasmacytoid dendritic cell cytokine production [BP], 3 iron, 4 sulfur cluster binding [MF], succinate dehydrogenase (ubiquinone) activity [MF], negative regulation of egress of virus within host cell [BP], methionyl-tRNA formyltransferase activity [MF], seminal clot liquefaction [BP] |
CG_h1r2_promoter_n_PM_12_188_6 | ![]() |
![]() |
1 | 0.25 | 3.38E-05 | SLC13A3, MGLL, ATF2, AQP7 | high affinity sodium:dicarboxylate symporter activity [MF], urea channel activity [MF], positive regulation of transforming growth factor beta2 production [BP], regulation of endocannabinoid signaling pathway [BP] |
CG_h1r2_promoter_n_PM_12_235_6 | ![]() |
![]() |
2 | 0.5 | 7.94E-05 | TK2, ROCK2, SLC25A1 | mitochondrial citrate transport [BP], deoxycytidine metabolic process [BP], positive regulation of centrosome duplication [BP] |
CG_h1r2_promoter_n_PM_12_17_4 | ![]() |
![]() |
1 | 0.25 | 1.69E-04 | SLC25A29, MAD1L1 | mitotic telophase [BP], acyl carnitine transmembrane transporter activity [MF] |
CG_h1r2_promoter_n_PM_12_195_8 | ![]() |
![]() |
1 | 0.25 | 9.23E-05 | HDAC4, CKB, GAMT | A band [CC], creatine metabolic process [BP] |
CG_h1r2_promoter_n_PM_12_108_8 | ![]() |
![]() |
2 | 0.25 | 2.29E-04 | DPYSL3, MIEN1 | positive regulation of filopodium assembly [BP] |
CG_h1r2_promoter_n_PM_12_152_17 | ![]() |
![]() |
2 | 0.5 | 1.19E-04 | FBP1 | cellular response to magnesium ion [BP], fructose 1,6-bisphosphate 1-phosphatase activity [MF] |
CG_h1r2_promoter_n_PM_12_22_5 | ![]() |
![]() |
2 | 0.5 | 7.95E-05 | POMGNT1 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase activity [MF] |
CG_h1r2_promoter_n_PM_12_259_13 | ![]() |
![]() |
2 | 0.5 | 4.26E-05 | LGMN, KIAA0368, CLPX | late endosome [CC], mitochondrial endopeptidase Clp complex [CC] |
CG_h1r2_promoter_n_PM_12_27_17 | ![]() |
![]() |
2 | 0.5 | 7.32E-05 | NAGA, BAZ1B | vitamin D receptor activator activity [MF], alpha-N-acetylgalactosaminidase activity [MF], DNA replication-dependent nucleosome disassembly [BP] |
CG_h1r2_promoter_n_PM_12_35_16 | ![]() |
![]() |
1 | 0.25 | 9.23E-06 | COL11A1 | collagen type XI [CC] |
CG_h1r2_promoter_n_PM_12_98_9 | ![]() |
![]() |
3 | 0.5 | 4.54E-05 | ANKLE2 | mitotic nuclear envelope reassembly [BP] |
CG_h1r2_promoter_n_PM_12_200_4 | ![]() |
![]() |
1 | 0.25 | 1.68E-05 | HYI | hydroxypyruvate isomerase activity [MF] |
CG_h1r2_promoter_n_PM_12_205_12 | ![]() |
![]() |
1 | 0.25 | 2.21E-04 | ACSS1, EDN2, RPA3, BRCA1 | double-strand break repair via homologous recombination [BP], fatty acid biosynthetic process [BP], propionate biosynthetic process [BP], positive regulation of histone H4-K16 acetylation [BP], positive regulation of histone H3-K9 acetylation [BP], positive regulation of histone H4-K20 methylation [BP], hormonal regulation of the force of heart contraction [BP], acetate biosynthetic process [BP] |
CG_h1r2_promoter_n_PM_12_84_7 | ![]() |
![]() |
1 | 0.25 | 1.01E-05 | NRP1 | positive regulation of cytokine activity [BP], trigeminal nerve morphogenesis [BP] |
CG_h1r2_promoter_n_PM_14_5_20 | ![]() |
![]() |
6 | 1.0 | 6.73E-05 | ATXN3, JOSD2 | omega peptidase activity [MF] |
CG_h1r2_promoter_n_PM_12_65_3 | ![]() |
![]() |
2 | 0.5 | 1.55E-05 | FHIT, APOD | negative regulation of cytokine production involved in inflammatory response [BP], negative regulation of lipoprotein lipid oxidation [BP], negative regulation of smooth muscle cell-matrix adhesion [BP], negative regulation of T cell migration [BP], bis(5'-adenosyl)-triphosphatase activity [MF] |
CG_h1r2_promoter_n_PM_12_190_9 | ![]() |
![]() |
2 | 0.5 | 7.52E-05 | CYBA, TRIT1, NAGA, HLA-C | alpha-N-acetylgalactosaminidase activity [MF], smooth muscle hypertrophy [BP], tRNA dimethylallyltransferase activity [MF], phagocytic vesicle membrane [CC], negative regulation of glomerular filtration by angiotensin [BP] |
CG_h1r2_promoter_n_PM_12_7_5 | ![]() |
![]() |
3 | 0.5 | 1.59E-04 | DMGDH, SLC28A3 | purine-specific nucleoside:sodium symporter activity [MF], pyrimidine- and adenine-specific:sodium symporter activity [MF], dimethylglycine dehydrogenase activity [MF] |
CG_h1r2_promoter_n_PM_12_251_12 | ![]() |
![]() |
3 | 0.5 | 1.29E-04 | P2RX1 | ceramide biosynthetic process [BP], external side of cell outer membrane [CC] |
CG_h1r2_promoter_n_PM_12_234_5 | ![]() |
![]() |
2 | 0.5 | 1.23E-04 | MMAB, SLC25A16 | water-soluble vitamin metabolic process [BP], cob(I)yrinic acid a,c-diamide adenosyltransferase activity [MF] |
CG_h1r2_promoter_n_PM_12_109_11 | ![]() |
![]() |
1 | 0.25 | 2.01E-05 | GAMT | guanidinoacetate N-methyltransferase activity [MF], creatine biosynthetic process [BP] |
CG_h1r2_promoter_n_PM_12_207_5 | ![]() |
![]() |
1 | 0.25 | 3.67E-06 | MAP6D1 | N-terminal peptidyl-L-cysteine N-palmitoylation [BP] |
CG_h1r2_promoter_n_PM_12_215_9 | ![]() |
![]() |
2 | 0.5 | 1.14E-04 | TAS2R19, MTOR | regulation of carbohydrate utilization [BP], sensory perception of taste [BP], mTOR-FKBP12-rapamycin complex [CC], TOR signaling cascade [BP] |
CG_h1r2_promoter_n_PM_12_182_11 | ![]() |
![]() |
3 | 0.5 | 5.83E-05 | COL12A1, P4HA1 | collagen fibril organization [BP] |
CG_h1r2_promoter_n_PM_14_14_9 | ![]() |
![]() |
1 | 0.25 | 3.43E-04 | HBEGF, PCSK1N, RCHY1, COL1A1, HACL1 | negative regulation of elastin biosynthetic process [BP], collagen type I [CC], receptor binding [MF] |
CG_h1r2_promoter_n_PM_12_262_9 | ![]() |
![]() |
1 | 0.25 | 1.18E-04 | WNT4 | mesenchymal to epithelial transition [BP], metanephric nephron morphogenesis [BP] |
CG_h1r2_promoter_n_PM_12_106_5 | ![]() |
![]() |
2 | 0.5 | 8.57E-05 | ABR, MAP4K5, FBLN5, MATN1 | negative regulation of neutrophil degranulation [BP], small GTPase regulator activity [MF], elastic fiber [CC], growth plate cartilage chondrocyte morphogenesis [BP] |
CG_h1r2_promoter_n_PM_14_8_5 | ![]() |
![]() |
1 | 0.25 | 2.99E-05 | CLIP1, TPMT, FOXL2, ASPH | thiopurine S-methyltransferase activity [MF], female somatic sex determination [BP], menstruation [BP], endosome [CC], peptide-aspartate beta-dioxygenase activity [MF], macropinosome [CC] |
CG_h1r2_promoter_n_PM_12_55_5 | ![]() |
![]() |
2 | 0.5 | 1.95E-04 | NTRK3, SLC16A8 | lactate transmembrane transport [BP], lactate transmembrane transporter activity [MF], modulation by virus of host transcription [BP], lactate transport [BP], positive regulation of axon extension involved in regeneration [BP] |
CG_h1r2_promoter_n_PM_12_91_6 | ![]() |
![]() |
2 | 0.5 | 1.78E-04 | NEFL, MAP4K1 | neurofilament bundle assembly [BP], MAP kinase kinase kinase kinase activity [MF] |
CG_h1r2_promoter_n_PM_14_42_8 | ![]() |
![]() |
1 | 0.25 | 4.57E-05 | PDLIM7, YWHAG, SORBS1 | cell-substrate adherens junction [CC], focal adhesion [CC], protein kinase C inhibitor activity [MF], stress fiber [CC], insulin receptor complex [CC] |
CG_h1r2_promoter_n_PM_12_128_17 | ![]() |
![]() |
2 | 0.5 | 2.07E-04 | SLC19A2, OPLAH, GLRX2, PTGES2 | glutathione metabolic process [BP], protein disulfide oxidoreductase activity [MF], thiamine transmembrane transport [BP], 5-oxoprolinase (ATP-hydrolyzing) activity [MF], cell redox homeostasis [BP], arsenate reductase (glutaredoxin) activity [MF], thiamine transport [BP] |
CG_h1r2_promoter_n_PM_12_12_5 | ![]() |
![]() |
2 | 0.5 | 1.62E-05 | CSGALNACT1, KISS1 | kisspeptin receptor binding [MF], peptidoglycan glycosyltransferase activity [MF] |
CG_h1r2_promoter_n_PM_12_232_12 | ![]() |
![]() |
3 | 0.75 | 8.11E-05 | ASGR2 | asialoglycoprotein receptor activity [MF] |
CG_h1r2_promoter_n_PM_12_137_15 | ![]() |
![]() |
2 | 0.5 | 4.98E-04 | MEF2C | epithelial cell proliferation involved in renal tubule morphogenesis [BP], sinoatrial valve morphogenesis [BP], cellular response to trichostatin A [BP], positive regulation of macrophage apoptotic process [BP], regulation of synaptic activity [BP], muscle cell fate determination [BP], positive regulation of alkaline phosphatase activity [BP], positive regulation of behavioral fear response [BP], primary heart field specification [BP] |
CG_h1r2_promoter_n_PM_12_275_7 | ![]() |
![]() |
2 | 0.25 | 1.10E-04 | CHEK2 | signal transduction involved in intra-S DNA damage checkpoint [BP] |
CG_h1r2_promoter_n_PM_12_97_9 | ![]() |
![]() |
3 | 0.5 | 4.66E-05 | SLC33A1 | acetyl-CoA transporter activity [MF], acetyl-CoA transport [BP] |
CG_h1r2_promoter_n_PM_12_184_8 | ![]() |
![]() |
2 | 0.5 | 3.66E-05 | SALL1, WIPI1, HDAC5, GNPTAB | ureteric bud invasion [BP], carbohydrate phosphorylation [BP], olfactory bulb mitral cell layer development [BP], vesicle targeting, trans-Golgi to endosome [BP], histone deacetylase complex [CC], histone deacetylation [BP], histone deacetylase activity [MF], inductive cell-cell signaling [BP], UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity [MF] |
CG_h1r2_promoter_n_PM_12_213_5 | ![]() |
![]() |
1 | 0.25 | 2.69E-05 | SLCO2A1, SLC35B1 | prostaglandin transmembrane transporter activity [MF], lipid transporter activity [MF], UDP-galactose transmembrane transport [BP], UDP-galactose transmembrane transporter activity [MF] |
CG_h1r2_promoter_n_PM_12_260_4 | ![]() |
![]() |
1 | 0.25 | 1.78E-04 | CTC1 | Stn1-Ten1 complex [CC] |
CG_h1r2_promoter_n_PM_12_105_6 | ![]() |
![]() |
3 | 0.75 | 3.41E-05 | USP34, SFRP1 | stromal-epithelial cell signaling involved in prostate gland development [BP], convergent extension involved in somitogenesis [BP], positive regulation of fibroblast apoptotic process [BP], cysteine-type endopeptidase activity [MF], positive regulation of canonical Wnt receptor signaling pathway [BP], negative regulation of canonical Wnt receptor signaling pathway involved in controlling type B pancreatic cell proliferation [BP] |
CG_h1r2_promoter_n_PM_14_28_6 | ![]() |
![]() |
3 | 0.75 | 4.63E-05 | GNE, PYCARD | positive regulation of antigen processing and presentation of peptide antigen via MHC class II [BP], Pyrin domain binding [MF], N-acylmannosamine kinase activity [MF], N-acetylglucosamine biosynthetic process [BP], N-acetylneuraminate biosynthetic process [BP], myeloid dendritic cell activation involved in immune response [BP], UDP-N-acetylglucosamine 2-epimerase activity [MF] |
CG_h1r2_promoter_n_PM_12_186_6 | ![]() |
![]() |
3 | 0.5 | 6.77E-05 | CPLX1 | glutamate secretion [BP] |
CG_h1r2_promoter_n_PM_14_19_7 | ![]() |
![]() |
3 | 0.5 | 8.25E-05 | TSC1, CCBL1 | glutamine-phenylpyruvate transaminase activity [MF], rRNA export from nucleus [BP], L-phenylalanine:pyruvate aminotransferase activity [MF], L-phenylalanine-oxaloacetate transaminase activity [MF], L-glutamine:pyruvate aminotransferase activity [MF], myelination [BP] |
CG_h1r2_promoter_n_PM_12_209_7 | ![]() |
![]() |
2 | 0.5 | 8.35E-05 | PLA2G4F, PLA2G2C | calcium-dependent phospholipase A2 activity [MF] |
CG_h1r2_promoter_n_PM_12_81_5 | ![]() |
![]() |
2 | 0.5 | 1.07E-04 | AKR7A3, CLCF1 | CNTFR-CLCF1 complex [CC], aflatoxin catabolic process [BP] |
CG_h1r2_promoter_n_PM_14_31_4 | ![]() |
![]() |
1 | 0.25 | 4.57E-05 | DLX2, LONP1 | mitochondrial heavy strand promoter anti-sense binding [MF], oxidation-dependent protein catabolic process [BP], single-stranded RNA binding [MF], mitochondrial light strand promoter anti-sense binding [MF] |
CG_h1r2_promoter_n_PM_12_69_13 | ![]() |
![]() |
2 | 0.5 | 3.66E-05 | TMED10 | gamma-secretase complex [CC], beta-amyloid formation [BP] |
CG_h1r2_promoter_n_PM_12_172_10 | ![]() |
![]() |
4 | 0.75 | 3.35E-05 | ANGPT1, LHX3 | medial motor column neuron differentiation [BP], regulation of satellite cell proliferation [BP] |
CG_h1r2_promoter_n_PM_12_230_7 | ![]() |
![]() |
1 | 0.25 | 7.92E-05 | CSGALNACT1 | peptidoglycan glycosyltransferase activity [MF] |
CG_h1r2_promoter_n_PM_12_189_8 | ![]() |
![]() |
2 | 0.5 | 4.83E-05 | GDI2 | Rab GDP-dissociation inhibitor activity [MF] |
CG_h1r2_promoter_n_PM_12_220_9 | ![]() |
![]() |
2 | 0.5 | 2.89E-05 | NCOR2, TNFRSF1A, FOSL1 | vitellogenesis [BP], tumor necrosis factor binding [MF], regulation of cellular ketone metabolic process by negative regulation of transcription from RNA polymerase II promoter [BP] |
CG_h1r2_promoter_n_PM_12_157_7 | ![]() |
![]() |
2 | 0.25 | 9.38E-06 | NUAK1 | regulation of myosin-light-chain-phosphatase activity [BP] |
CG_h1r2_promoter_n_PM_12_166_14 | ![]() |
![]() |
2 | 0.25 | 1.44E-04 | MC2R | corticotropin receptor activity [MF] |
CG_h1r2_promoter_n_PM_12_116_6 | ![]() |
![]() |
2 | 0.5 | 2.21E-04 | TAS1R2 | detection of chemical stimulus involved in sensory perception of sweet taste [BP], sweet taste receptor activity [MF] |
CG_h1r2_promoter_n_PM_12_291_5 | ![]() |
![]() |
2 | 0.5 | 1.31E-05 | CCL19 | CCR7 chemokine receptor binding [MF], positive regulation of dendritic cell dendrite assembly [BP] |
CG_h1r2_promoter_n_PM_12_278_8 | ![]() |
![]() |
2 | 0.5 | 2.20E-04 | DHFRL1 | thymidine biosynthetic process [BP], dihydrofolate reductase activity [MF] |
CG_h1r2_promoter_n_PM_14_7_13 | ![]() |
![]() |
2 | 0.5 | 5.63E-05 | SNX5, MBTPS1, ERO1L | macropinocytic cup [CC], endoplasmic reticulum unfolded protein response [BP] |
CG_h1r2_promoter_n_PM_12_103_12 | ![]() |
![]() |
2 | 0.25 | 3.12E-05 | ECE1, EYA1 | substance P catabolic process [BP], Weibel-Palade body [CC], pharyngeal system development [BP], calcitonin catabolic process [BP], endothelin maturation [BP], intrinsic to endosome membrane [CC] |
CG_h1r2_promoter_n_PM_14_11_12 | ![]() |
![]() |
3 | 0.75 | 3.75E-05 | RNH1 | angiogenin-PRI complex [CC], ribonuclease inhibitor activity [MF] |
CG_h1r2_promoter_n_PM_12_148_10 | ![]() |
![]() |
1 | 0.25 | 1.95E-04 | WARS, IDH2 | isocitrate dehydrogenase (NADP+) activity [MF], tryptophan-tRNA ligase activity [MF], glyoxylate cycle [BP], tryptophanyl-tRNA aminoacylation [BP] |
CG_h1r2_promoter_n_PM_12_164_10 | ![]() |
![]() |
5 | 0.75 | 3.23E-05 | GOT1 | L-aspartate:2-oxoglutarate aminotransferase activity [MF], glutamate catabolic process to aspartate [BP], L-phenylalanine:2-oxoglutarate aminotransferase activity [MF], glutamate catabolic process to 2-oxoglutarate [BP], phosphatidylserine decarboxylase activity [MF], aspartate catabolic process [BP], aspartate biosynthetic process [BP], glycerol biosynthetic process [BP] |
CG_h1r2_promoter_n_PM_12_294_13 | ![]() |
![]() |
2 | 0.5 | 1.66E-05 | MAP2K2 | peptidyl-serine autophosphorylation [BP] |
CG_h1r2_promoter_n_PM_12_219_4 | ![]() |
![]() |
2 | 0.5 | 4.23E-05 | NAGPA | N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase activity [MF] |
CG_h1r2_promoter_n_PM_14_48_13 | ![]() |
![]() |
4 | 0.5 | 2.97E-05 | GDE1, BAZ1B | vitamin D receptor activator activity [MF], DNA replication-dependent nucleosome disassembly [BP], glycerophosphoinositol glycerophosphodiesterase activity [MF] |
CG_h1r2_promoter_n_PM_14_64_13 | ![]() |
![]() |
1 | 0.25 | 2.52E-05 | BAZ1B, DLX2, ANKH | vitamin D receptor activator activity [MF], inorganic diphosphate transport [BP], cerebral cortex GABAergic interneuron fate commitment [BP], regulation of transcription from RNA polymerase II promoter involved in forebrain neuron fate commitment [BP], inorganic diphosphate transmembrane transporter activity [MF], DNA replication-dependent nucleosome disassembly [BP] |
CG_h1r2_promoter_n_PM_12_31_15 | ![]() |
![]() |
3 | 0.75 | 2.18E-05 | AHI1 | pronephric nephron tubule morphogenesis [BP], pronephric duct morphogenesis [BP], positive regulation of polarized epithelial cell differentiation [BP], Kupffer's vesicle development [BP] |
CG_h1r2_promoter_n_PM_12_51_5 | ![]() |
![]() |
2 | 0.5 | 9.32E-05 | TNNI3, AGMAT, SLC30A1 | calcium channel inhibitor activity [MF], negative regulation of zinc ion transmembrane import [BP], agmatinase activity [MF], putrescine biosynthetic process from arginine [BP] |
CG_h1r2_promoter_n_PM_12_79_8 | ![]() |
![]() |
1 | 0.25 | 1.67E-04 | CCL3, ZC3H3, PODXL | epithelial tube formation [BP], regulation of mRNA export from nucleus [BP], regulation of microvillus assembly [BP], CCR5 chemokine receptor binding [MF], calcium-dependent protein kinase C activity [MF] |
CG_h1r2_promoter_n_PM_12_112_8 | ![]() |
![]() |
2 | 0.5 | 9.88E-05 | HBB, DDAH2 | positive regulation of nitric oxide biosynthetic process [BP] |
CG_h1r2_promoter_n_PM_12_159_9 | ![]() |
![]() |
1 | 0.25 | 7.30E-05 | MYH15, MYH8 | myosin filament [CC] |
CG_h1r2_promoter_n_PM_12_99_8 | ![]() |
![]() |
2 | 0.25 | 4.60E-05 | SLC2A5 | fructose transmembrane transporter activity [MF], fructose transport [BP] |
CG_h1r2_promoter_n_PM_12_201_7 | ![]() |
![]() |
1 | 0.25 | 4.85E-05 | SLC11A2, CITED1 | vanadium ion transmembrane transporter activity [MF], response to interleukin-11 [BP], nickel cation transport [BP], cadmium ion transmembrane transporter activity [MF], ferrous iron import [BP], lead ion transport [BP], ferrous iron transport [BP], paraferritin complex [CC], nickel cation transmembrane transport [BP], lead ion transmembrane transporter activity [MF], vanadium ion transport [BP] |
CG_h1r2_promoter_n_PM_12_63_7 | ![]() |
![]() |
1 | 0.25 | 5.62E-05 | AKR7A2 | phenanthrene-9,10-epoxide hydrolase activity [MF] |
CG_h1r2_promoter_n_PM_14_57_6 | ![]() |
![]() |
3 | 0.5 | 1.12E-05 | LONP1, MSRB1, PRKAG1 | mitochondrial heavy strand promoter anti-sense binding [MF], mitochondrial light strand promoter anti-sense binding [MF], oxidation-dependent protein catabolic process [BP], ADP binding [MF], methionine-R-sulfoxide reductase activity [MF] |
CG_h1r2_promoter_n_PM_14_47_10 | ![]() |
![]() |
2 | 0.5 | 3.90E-05 | AKR7A3 | aflatoxin catabolic process [BP] |
CG_h1r2_promoter_n_PM_12_266_4 | ![]() |
![]() |
1 | 0.25 | 2.35E-05 | CASP3, HAND1 | cardiac left ventricle formation [BP], nuclear fragmentation involved in apoptotic nuclear change [BP], cardiac right ventricle formation [BP], embryonic heart tube formation [BP], negative regulation of activated T cell proliferation [BP], heart development [BP] |
CG_h1r2_promoter_n_PM_12_170_7 | ![]() |
![]() |
2 | 0.5 | 5.08E-05 | SNAPC4 | snRNA-activating protein complex [CC], snRNA transcription from RNA polymerase III promoter [BP], snRNA transcription from RNA polymerase II promoter [BP] |
CG_h1r2_promoter_n_PM_12_92_10 | ![]() |
![]() |
2 | 0.5 | 6.58E-05 | CENPJ, MMP7 | gamma-tubulin small complex [CC], antibacterial peptide secretion [BP] |
CG_h1r2_promoter_n_PM_14_37_8 | ![]() |
![]() |
2 | 0.5 | 2.11E-04 | A4GALT, CARS | cysteinyl-tRNA aminoacylation [BP], lactosylceramide 4-alpha-galactosyltransferase activity [MF], cysteine-tRNA ligase activity [MF] |
CG_h1r2_promoter_n_PM_12_301_10 | ![]() |
![]() |
1 | 0.25 | 5.52E-05 | UIMC1, PMM1 | phosphomannomutase activity [MF], mannose biosynthetic process [BP], histone H2A K63-linked deubiquitination [BP] |
CG_h1r2_promoter_n_PM_12_212_4 | ![]() |
![]() |
1 | 0.25 | 2.98E-05 | TLR9 | positive regulation of interleukin-18 production [BP] |
CG_h1r2_promoter_n_PM_12_39_5 | ![]() |
![]() |
1 | 0.25 | 5.03E-05 | DLG4, RNASET2 | P2Y1 nucleotide receptor binding [MF], ribonuclease T2 activity [MF] |
CG_h1r2_promoter_n_PM_12_16_10 | ![]() |
![]() |
2 | 0.5 | 4.51E-05 | TGDS | dTDP-glucose 4,6-dehydratase activity [MF] |
CG_h1r2_promoter_n_PM_12_192_11 | ![]() |
![]() |
2 | 0.5 | 2.55E-05 | LAMP3, CARS2 | cysteinyl-tRNA aminoacylation [BP], alveolar lamellar body membrane [CC], cysteine-tRNA ligase activity [MF] |
CG_h1r2_promoter_n_PM_12_178_8 | ![]() |
![]() |
2 | 0.25 | 2.15E-04 | STAT1 | negative regulation of metanephric nephron tubule epithelial cell differentiation [BP] |
CG_h1r2_promoter_n_PM_14_9_6 | ![]() |
![]() |
2 | 0.5 | 1.81E-05 | CYB561 | transmembrane electron transfer carrier [MF] |
CG_h1r2_promoter_n_PM_12_248_6 | ![]() |
![]() |
2 | 0.25 | 3.35E-05 | PHKA2, SLC19A2 | thiamine transmembrane transport [BP], thiamine transport [BP], phosphorylase kinase complex [CC], thiamine transmembrane transporter activity [MF], thiamine uptake transmembrane transporter activity [MF] |
CG_h1r2_promoter_n_PM_12_168_12 | ![]() |
![]() |
2 | 0.5 | 2.97E-05 | DEFA1B | azurophil granule lumen [CC] |
CG_h1r2_promoter_n_PM_12_121_4 | ![]() |
![]() |
1 | 0.25 | 1.24E-04 | FLT1 | vascular endothelial growth factor receptor-1 signaling pathway [BP], VEGF-B-activated receptor activity [MF], VEGF-A-activated receptor activity [MF], placental growth factor-activated receptor activity [MF] |
CG_h1r2_promoter_n_PM_12_85_7 | ![]() |
![]() |
2 | 0.5 | 5.73E-05 | NTAN1, PTK2, MAP3K7, BRCA1 | positive regulation of histone H3-K9 acetylation [BP], protein-N-terminal asparagine amidohydrolase activity [MF], histone H3 acetylation [BP], positive regulation of histone H4-K16 acetylation [BP], netrin-activated signaling pathway [BP], positive regulation of histone H4-K20 methylation [BP] |
CG_h1r2_promoter_n_PM_12_177_13 | ![]() |
![]() |
2 | 0.5 | 6.36E-05 | BDH1, IDH1 | 3-hydroxybutyrate dehydrogenase activity [MF], isocitrate dehydrogenase (NADP+) activity [MF], glyoxylate cycle [BP] |
CG_h1r2_promoter_n_PM_12_153_4 | ![]() |
![]() |
1 | 0.25 | 8.78E-05 | TAL1 | hemangioblast cell differentiation [BP], Lsd1/2 complex [CC] |
CG_h1r2_promoter_n_PM_12_258_6 | ![]() |
![]() |
2 | 0.5 | 1.55E-04 | PTK2, FBXO31, RHOA | phosphatidylinositol-mediated signaling [BP], negative regulation of axonogenesis [BP], protein ubiquitination [BP], response to glucose stimulus [BP], positive regulation of cell growth [BP], mitotic cell cycle G1/S transition DNA damage checkpoint [BP], regulation of axonogenesis [BP], lamellipodium [CC], netrin-activated signaling pathway [BP], response to mechanical stimulus [BP], positive regulation of cell adhesion [BP] |
CG_h1r2_promoter_n_PM_12_269_11 | ![]() |
![]() |
2 | 0.5 | 1.07E-04 | DHCR24, MOCS2 | oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor [MF], delta24-sterol reductase activity [MF], Mo-molybdopterin synthase activity [MF] |
CG_h1r2_promoter_n_PM_12_273_15 | ![]() |
![]() |
2 | 0.5 | 7.24E-05 | KLK14, QDPR | NADH binding [MF], 6,7-dihydropteridine reductase activity [MF], seminal clot liquefaction [BP] |
CG_h1r2_promoter_n_PM_12_272_15 | ![]() |
![]() |
2 | 0.5 | 1.36E-04 | SLC25A17, INTS4, TUT1 | NAD transporter activity [MF], FAD transmembrane transporter activity [MF], snRNA processing [BP], FMN transmembrane transporter activity [MF], FAD transmembrane transport [BP] |
CG_h1r2_promoter_n_PM_14_1_47 | ![]() |
![]() |
4 | 0.75 | 6.43E-05 | CHST10, PJA2, SGK1, NCOR1, FUT7 | CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation [BP], long-term memory [BP] |
CG_h1r2_promoter_n_PM_12_174_4 | ![]() |
![]() |
1 | 0.25 | 2.00E-04 | MKKS, MPP7, IL18 | positive regulation of blood vessel remodeling [BP], positive regulation of male germ cell proliferation [BP], interleukin-13 biosynthetic process [BP], negative regulation of appetite by leptin-mediated signaling pathway [BP], pigment granule aggregation in cell center [BP], protein localization to adherens junction [BP], MPP7-DLG1-LIN7 complex [CC], positive regulation of NK T cell proliferation [BP] |
CG_h1r2_promoter_n_PM_12_160_6 | ![]() |
![]() |
1 | 0.25 | 2.95E-04 | MGAT4A | alpha-1,3-mannosylglycoprotein 4-beta-N-acetylglucosaminyltransferase activity [MF] |
CG_h1r2_promoter_n_PM_14_30_34 | ![]() |
![]() |
3 | 0.75 | 4.13E-05 | SLC2A2 | hexose transmembrane transport [BP] |
CG_h1r2_promoter_n_PM_12_171_11 | ![]() |
![]() |
1 | 0.25 | 6.45E-05 | ENPP6 | glycerophosphocholine cholinephosphodiesterase activity [MF] |
CG_h1r2_promoter_n_PM_12_293_9 | ![]() |
![]() |
1 | 0.25 | 1.07E-04 | ZBP1, MBOAT4, TEX14 | intercellular bridge organization [BP], left-handed Z-DNA binding [MF], peptidyl-serine octanoylation [BP], serine O-acyltransferase activity [MF] |
CG_h1r2_promoter_n_PM_12_87_6 | ![]() |
![]() |
2 | 0.5 | 1.15E-04 | NUDT12, MBP, SLC6A3 | protease binding [MF], NAD catabolic process [BP], dopamine:sodium symporter activity [MF], monoamine transport [BP], NAD+ diphosphatase activity [MF] |
CG_h1r2_promoter_n_PM_12_120_12 | ![]() |
![]() |
1 | 0.25 | 1.67E-04 | GHRL | ghrelin receptor binding [MF] |
CG_h1r2_promoter_n_PM_12_151_5 | ![]() |
![]() |
1 | 0.25 | 1.20E-04 | MKX, LAMTOR1 | tendon sheath development [BP], endosome localization [BP] |
CG_h1r2_promoter_n_PM_12_1_12 | ![]() |
![]() |
2 | 0.5 | 7.85E-05 | IL22, CRLF1, NSMF | apical dendrite [CC], negative regulation of motor neuron apoptotic process [BP], interleukin-22 receptor binding [MF] |
CG_h1r2_promoter_n_PM_12_123_8 | ![]() |
![]() |
1 | 0.25 | 5.98E-05 | PPP2R2B, ADAM8 | alpha9-beta1 integrin-vascular cell adhesion molecule-1 complex [CC], positive regulation of tumor necrosis factor (ligand) superfamily member 11 production [BP], tertiary granule [CC], positive regulation of neutrophil extravasation [BP], positive regulation of fibronectin-dependent thymocyte migration [BP], activation of MAPK activity involved in innate immune response [BP], dense core granule membrane [CC], phagolysosome [CC], alpha9-beta1 integrin-ADAM8 complex [CC], positive regulation of eosinophil migration [BP], regulation of protein phosphatase type 2A activity [BP] |
CG_h1r2_promoter_n_PM_12_93_9 | ![]() |
![]() |
1 | 0.25 | 4.11E-05 | NKX2-2 | ventral spinal cord interneuron fate determination [BP], type B pancreatic cell fate commitment [BP] |
CG_h1r2_promoter_n_PM_12_41_7 | ![]() |
![]() |
3 | 0.5 | 1.14E-05 | APTX, SNAPC4, PC | snRNA-activating protein complex [CC], DNA 5'-adenosine monophosphate hydrolase activity [MF], snRNA transcription from RNA polymerase III promoter [BP], snRNA transcription from RNA polymerase II promoter [BP], pyruvate carboxylase activity [MF] |
CG_h1r2_promoter_n_PM_14_61_13 | ![]() |
![]() |
1 | 0.25 | 2.02E-04 | DNA2, CELSR1, PPP1R13L | protein localization involved in establishment of planar polarity [BP], lateral sprouting involved in lung morphogenesis [BP], hair cycle [BP], establishment of body hair planar orientation [BP], mitochondrial DNA repair [BP], site-specific endodeoxyribonuclease activity, specific for altered base [MF], orthogonal dichotomous subdivision of terminal units involved in lung branching morphogenesis [BP], planar dichotomous subdivision of terminal units involved in lung branching morphogenesis [BP], gamma DNA polymerase complex [CC] |
CG_h1r2_promoter_n_PM_12_34_10 | ![]() |
![]() |
2 | 0.25 | 1.36E-04 | ROR2, CYP51A1, SOX10 | negative regulation of canonical Wnt receptor signaling pathway [BP], extrinsic to mitochondrial outer membrane [CC], cholesterol biosynthetic process via 24,25-dihydrolanosterol [BP], sterol 14-demethylase activity [MF] |
CG_h1r2_promoter_n_PM_14_46_14 | ![]() |
![]() |
2 | 0.5 | 3.58E-05 | PTH, PIGF | ethanolaminephosphotransferase activity [MF], parathyroid hormone receptor binding [MF] |
CG_h1r2_promoter_n_PM_12_279_7 | ![]() |
![]() |
3 | 0.5 | 7.93E-05 | UNC13D, NR4A2 | habenula development [BP], granuloma formation [BP] |
CG_h1r2_promoter_n_PM_12_83_5 | ![]() |
![]() |
1 | 0.25 | 2.38E-04 | IL5 | positive regulation of eosinophil differentiation [BP] |
CG_h1r2_promoter_n_PM_14_53_6 | ![]() |
![]() |
1 | 0.25 | 1.93E-05 | SYCP3, ADRA2B, SPAG9, EIF2AK1 | spermatogenesis, exchange of chromosomal proteins [BP], positive regulation of neuron differentiation [BP], negative regulation of translational initiation by iron [BP], negative regulation of hemoglobin biosynthetic process [BP] |
CG_h1r2_promoter_n_PM_12_142_9 | ![]() |
![]() |
3 | 0.5 | 1.17E-04 | ENTPD4, BCL11A, ACVR1 | endocardial cushion cell fate commitment [BP], protein sumoylation [BP], UDP catabolic process [BP] |
CG_h1r2_promoter_n_PM_12_133_5 | ![]() |
![]() |
1 | 0.25 | 2.09E-04 | DNAJC2, SIRT2 | ubiquitin binding [MF] |
CG_h1r2_promoter_n_PM_12_42_8 | ![]() |
![]() |
1 | 0.25 | 5.66E-05 | AKT1, DEDD2, BST2, MTFMT | methionyl-tRNA formyltransferase activity [MF], intracellular signal transduction [BP], negative regulation of egress of virus within host cell [BP], glycogen cell differentiation involved in embryonic placenta development [BP], negative regulation of plasmacytoid dendritic cell cytokine production [BP] |
CG_h1r2_promoter_n_PM_12_289_7 | ![]() |
![]() |
1 | 0.25 | 8.04E-05 | LIPE, SLC17A7 | sequestering of neurotransmitter [BP], sodium:inorganic phosphate symporter activity [MF], hormone-sensitive lipase activity [MF] |
CG_h1r2_promoter_n_PM_12_64_12 | ![]() |
![]() |
2 | 0.5 | 1.56E-04 | GNPNAT1, ZDHHC11, ZDHHC19 | transferase activity, transferring acyl groups [MF], glucosamine 6-phosphate N-acetyltransferase activity [MF] |
CG_h1r2_promoter_n_PM_12_244_13 | ![]() |
![]() |
2 | 0.5 | 1.06E-04 | SGSH, SLC23A1 | N-sulfoglucosamine sulfohydrolase activity [MF], dehydroascorbic acid transport [BP] |
CG_h1r2_promoter_n_PM_12_227_12 | ![]() |
![]() |
1 | 0.25 | 2.01E-04 | ADRB3, IRF7, RPGRIP1L, GNPNAT1 | beta3-adrenergic receptor activity [MF], glucosamine 6-phosphate N-acetyltransferase activity [MF], regulation of MyD88-independent toll-like receptor signaling pathway [BP], thromboxane A2 receptor binding [MF] |
CG_h1r2_promoter_n_PM_12_8_15 | ![]() |
![]() |
3 | 0.5 | 1.54E-04 | CBS, MBOAT4, HOMER1, LPAR3, NLRC3, NFKBID | phospholipase C-activating G-protein coupled glutamate receptor signaling pathway [BP], peptidyl-serine octanoylation [BP], cystathionine beta-synthase activity [MF], positive regulation of calcium ion transport [BP], serine O-acyltransferase activity [MF], cysteine biosynthetic process via cystathionine [BP], negative regulation of NF-kappaB transcription factor activity [BP], homocysteine catabolic process [BP], transsulfuration [BP], cysteine biosynthetic process from serine [BP], hydrogen sulfide biosynthetic process [BP], type 5 metabotropic glutamate receptor binding [MF] |
CG_h1r2_promoter_n_PM_12_161_9 | ![]() |
![]() |
4 | 0.75 | 1.77E-04 | NLRP1, CCK, LIG4 | activation of cysteine-type endopeptidase activity involved in apoptotic process [BP], DNA ligation involved in DNA recombination [BP] |
CG_h1r2_promoter_n_PM_12_110_11 | ![]() |
![]() |
2 | 0.5 | 3.26E-05 | TERT, GSS | glutathione synthase activity [MF], telomeric template RNA reverse transcriptase activity [MF] |
CG_h1r2_promoter_n_PM_12_261_13 | ![]() |
![]() |
2 | 0.5 | 1.93E-04 | SNAPC4, SLC15A1 | snRNA transcription [BP], snRNA transcription from RNA polymerase III promoter [BP], peptide:hydrogen symporter activity [MF], proton-dependent oligopeptide secondary active transmembrane transporter activity [MF], snRNA-activating protein complex [CC], snRNA transcription from RNA polymerase II promoter [BP] |
CG_h1r2_promoter_n_PM_12_218_8 | ![]() |
![]() |
1 | 0.25 | 5.19E-05 | VIMP | regulation of nitric oxide metabolic process [BP] |
CG_h1r2_promoter_n_PM_12_173_11 | ![]() |
![]() |
2 | 0.5 | 1.07E-04 | ABCA1 | apolipoprotein A-I receptor activity [MF] |
CG_h1r2_promoter_n_PM_12_86_8 | ![]() |
![]() |
2 | 0.5 | 2.86E-04 | PDGFB, SLC25A17 | ADP transmembrane transporter activity [MF], FMN transmembrane transporter activity [MF], metanephric glomerular endothelium development [BP], metanephric glomerular mesangial cell development [BP], FAD transmembrane transporter activity [MF], NAD transporter activity [MF], ATP transmembrane transporter activity [MF], coenzyme A transmembrane transporter activity [MF], AMP transmembrane transporter activity [MF], FAD transmembrane transport [BP] |
CG_h1r2_promoter_n_PM_12_267_7 | ![]() |
![]() |
1 | 0.25 | 6.98E-05 | UBC, LTF | hypothalamus gonadotrophin-releasing hormone neuron development [BP], phagocytic vesicle lumen [CC] |
CG_h1r2_promoter_n_PM_12_156_7 | ![]() |
![]() |
1 | 0.25 | 1.16E-04 | HSPD1 | positive regulation of T cell mediated immune response to tumor cell [BP], B cell cytokine production [BP] |
CG_h1r2_promoter_n_PM_12_165_9 | ![]() |
![]() |
2 | 0.5 | 5.57E-05 | TERT, NPPC, GHSR | growth hormone secretagogue receptor activity [MF], telomeric template RNA reverse transcriptase activity [MF], regulation of multicellular organism growth [BP], cellular response to insulin stimulus [BP] |
CG_h1r2_promoter_n_PM_12_129_5 | ![]() |
![]() |
2 | 0.25 | 7.52E-06 | USP33, MTIF3, MAD2L2 | VCB complex [CC], zeta DNA polymerase complex [CC], ribosome disassembly [BP], negative regulation of mitotic anaphase-promoting complex activity [BP], negative regulation of cell-cell adhesion mediated by cadherin [BP] |
CG_h1r2_promoter_n_PM_12_25_6 | ![]() |
![]() |
2 | 0.5 | 9.86E-05 | CYP1A1 | flavonoid 3'-monooxygenase activity [MF], dibenzo-p-dioxin catabolic process [BP] |
CG_h1r2_promoter_n_PM_12_280_7 | ![]() |
![]() |
3 | 0.5 | 7.35E-05 | ADAM8 | alpha9-beta1 integrin-vascular cell adhesion molecule-1 complex [CC], positive regulation of tumor necrosis factor (ligand) superfamily member 11 production [BP], positive regulation of neutrophil extravasation [BP], positive regulation of fibronectin-dependent thymocyte migration [BP], activation of MAPK activity involved in innate immune response [BP], dense core granule membrane [CC], alpha9-beta1 integrin-ADAM8 complex [CC], positive regulation of eosinophil migration [BP] |
CG_h1r2_promoter_n_PM_12_179_12 | ![]() |
![]() |
2 | 0.5 | 5.79E-05 | MKNK2 | regulation of translation [BP] |
CG_h1r2_promoter_n_PM_12_249_7 | ![]() |
![]() |
2 | 0.5 | 2.52E-05 | NINJ2, FGF10, MBOAT4, STAT5B | positive regulation of urothelial cell proliferation [BP], mesenchymal-epithelial cell signaling involved in lung development [BP], positive regulation of white fat cell proliferation [BP], peptidyl-serine octanoylation [BP], serine O-acyltransferase activity [MF], urothelial cell proliferation [BP], positive regulation of mitotic cell cycle [BP], semicircular canal fusion [BP], bronchiole morphogenesis [BP], lung proximal/distal axis specification [BP], tissue regeneration [BP] |
CG_h1r2_promoter_n_PM_14_65_13 | ![]() |
![]() |
2 | 0.5 | 4.44E-05 | GHSR | growth hormone secretagogue receptor activity [MF] |
CG_h1r2_promoter_n_PM_12_265_6 | ![]() |
![]() |
1 | 0.25 | 2.53E-04 | PIR, NMNAT3 | nicotinamide-nucleotide adenylyltransferase activity [MF], quercetin 2,3-dioxygenase activity [MF], nicotinate-nucleotide adenylyltransferase activity [MF] |
CG_h1r2_promoter_n_PM_12_296_9 | ![]() |
![]() |
1 | 0.25 | 2.43E-04 | MYLK | aorta smooth muscle tissue morphogenesis [BP], myosin light chain kinase activity [MF] |
CG_h1r2_promoter_n_PM_12_246_8 | ![]() |
![]() |
2 | 0.25 | 1.79E-04 | SLC35B2 | 3'-phosphoadenosine 5'-phosphosulfate transport [BP], 3'-phosphoadenosine 5'-phosphosulfate transmembrane transporter activity [MF] |
CG_h1r2_promoter_n_PM_12_135_6 | ![]() |
![]() |
1 | 0.25 | 4.44E-05 | SLC22A8 | glutathione transport [BP], response to methotrexate [BP] |
CG_h1r2_promoter_n_PM_12_300_3 | ![]() |
![]() |
1 | 0.25 | 5.93E-05 | TFF2 | CXCR4 chemokine receptor binding [MF] |
CG_h1r2_promoter_n_PM_12_225_6 | ![]() |
![]() |
1 | 0.25 | 1.02E-04 | RHOA, UPF3B | positive regulation of translation [BP] |
CG_h1r2_promoter_n_PM_12_26_7 | ![]() |
![]() |
2 | 0.5 | 9.28E-05 | MAP6D1 | N-terminal peptidyl-L-cysteine N-palmitoylation [BP] |
CG_h1r2_promoter_n_PM_14_12_18 | ![]() |
![]() |
2 | 0.5 | 1.98E-05 | SLC6A13 | gamma-aminobutyric acid:sodium symporter activity [MF] |
CG_h1r2_promoter_n_PM_14_2_7 | ![]() |
![]() |
2 | 0.5 | 1.79E-05 | PPIP5K1, PIF1 | diphosphoinositol-pentakisphosphate kinase activity [MF], inositol-1,3,4,5,6-pentakisphosphate kinase activity [MF], ATP-dependent 5'-3' DNA helicase activity [MF], single-stranded DNA-dependent ATP-dependent DNA helicase activity [MF], ATP-dependent 5'-3' DNA/RNA helicase activity [MF] |
CG_h1r2_promoter_n_PM_12_150_8 | ![]() |
![]() |
2 | 0.25 | 1.59E-04 | CBS, GAS1 | cerebellum morphogenesis [BP] |
CG_h1r2_promoter_n_PM_12_223_17 | ![]() |
![]() |
2 | 0.5 | 3.63E-04 | AJUBA, SVIL | negative regulation of hippo signaling cascade [BP], regulation of cellular response to hypoxia [BP], actin filament binding [MF] |
CG_h1r2_promoter_n_PM_12_9_16 | ![]() |
![]() |
1 | 0.25 | 7.41E-05 | DCXR, LSM7, CNOT7, POLG2 | mitochondrial chromosome [CC], nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay [BP], L-xylulose reductase (NADP+) activity [MF] |
CG_h1r2_promoter_n_PM_12_263_11 | ![]() |
![]() |
2 | 0.5 | 2.75E-04 | MTOR, PRKAG2 | regulation of fatty acid oxidation [BP], peptidyl-threonine phosphorylation [BP], regulation of carbohydrate utilization [BP], mTOR-FKBP12-rapamycin complex [CC] |
CG_h1r2_promoter_n_PM_12_299_13 | ![]() |
![]() |
1 | 0.25 | 6.46E-05 | STIL, SEMA4C, JAG2 | neural tube closure [BP], morphogenesis of embryonic epithelium [BP] |
CG_h1r2_promoter_n_PM_14_17_5 | ![]() |
![]() |
3 | 0.75 | 2.64E-04 | KRT71, KRT4, KRT24, KRT3, ALDH7A1, KRT75 | structural molecule activity [MF], L-aminoadipate-semialdehyde dehydrogenase activity [MF], keratin filament [CC], betaine-aldehyde dehydrogenase activity [MF], intermediate filament cytoskeleton [CC], intermediate filament [CC] |
CG_h1r2_promoter_n_PM_12_242_6 | ![]() |
![]() |
3 | 0.5 | 6.39E-05 | CLIP1 | macropinosome [CC] |
CG_h1r2_promoter_n_PM_12_233_11 | ![]() |
![]() |
2 | 0.5 | 3.42E-04 | BAG5 | negative regulation of protein refolding [BP], regulation of inclusion body assembly [BP] |